VF
NEUP

Virtu Financial’s Neuphoria Therapeutics NEUP Stock Holding History

Virtu Financial’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,033
Closed -$49K – 2390
2026
Q1 		$49K Buy
+12,033
New +$50.9K ﹤0.01% 1292
2023
Q4 		– Sell
-1,380
Closed -$45K – 2101
2023
Q3 		$45K Buy
+1,380
New +$29.7K ﹤0.01% 921

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Virtu Financial's NEUP Position: Q2 2026 in Review

Virtu Financial sold out of Neuphoria Therapeutics (NEUP) in Q2 2026, closing a stake of 12,033 shares — an estimated $49K sold.

Virtu Financial first reported a position in NEUP in Q3 2023 and held it in 2 quarters. The position peaked at $49K in Q1 2026. 22 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • Virtu Financial reported no remaining Neuphoria Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 12,033 Neuphoria Therapeutics shares in Q2 2026, an estimated $49K.
  • Virtu Financial first reported a position in Neuphoria Therapeutics in Q3 2023 and held it in 2 quarters.
  • Virtu Financial's Neuphoria Therapeutics position peaked at $49K in Q1 2026.
  • 22 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.